KLF4 and cancer: Moreover, KLF4 can sensitize cancer cells to several established therapies, including cisplatin (124, 128, 171–173), cetuximab (22), mesalazine (174), and gefitinib (175), suggesting the potential for combinatory use with other anticancer drugs in future clinical trials.